An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on ...

NOVEMBER IS RECOGNIZED AS NATIONAL ALZHEIMER’S AWARENESS MONTH, A FIRST OF ITS KIND CLINICAL TRIAL IS CHANGING THE LIVES OF ...

Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in ...

Novo Nordisk shares plunge after its oral semaglutide Alzheimer’s trials fail, raising fresh doubts over its push into a ...

CHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed that the evoke and evoke+ clinical trials did not demonstrate a statistically significant reduction in Alzheimer's ...